4//SEC Filing
Casdin Private Growth Equity Fund, L.P. 4
Accession 0000899243-21-025300
CIK 0001840574other
Filed
Jun 21, 8:00 PM ET
Accepted
Jun 22, 5:12 PM ET
Size
8.2 KB
Accession
0000899243-21-025300
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2021-06-21+620,571→ 620,571 total - Conversion
Series B Preferred Stock
2021-06-21−5,746,183→ 0 total→ Common Stock (620,571 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
- [F2]The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001823061
Filing Metadata
- Form type
- 4
- Filed
- Jun 21, 8:00 PM ET
- Accepted
- Jun 22, 5:12 PM ET
- Size
- 8.2 KB